IMMUNOMEDICS INC's gross profit margin for the third quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. IMMUNOMEDICS INC is extremely liquid. Currently, the Quick Ratio is 11.81 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 73.94% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY15||Q3 FY14|
|Net Sales ($mil)||1.18||1.16|
|Net Income ($mil)||-11.76||-9.51|
|Balance Sheet||Q3 FY15||Q3 FY14|
|Cash & Equiv. ($mil)||106.19||20.93|
|Total Assets ($mil)||111.83||26.25|
|Total Debt ($mil)||96.44||0.0|
|Profitability||Q3 FY15||Q3 FY14|
|Gross Profit Margin||-930.54||-814.81|
|Return on Assets||-42.42||-119.07|
|Return on Equity||-887.56||-152.38|
|Debt||Q3 FY15||Q3 FY14|
|Share Data||Q3 FY15||Q3 FY14|
|Shares outstanding (mil)||93.45||83.48|
|Div / share||0.0||0.0|
|Book value / share||0.06||0.25|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||876100.0||920435.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 71.15 indicates a significant premium versus the S&P 500 average of 2.86 and a significant premium versus the industry average of 10.98. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, IMMUNOMEDICS INC proves to trade at a premium to investment alternatives within the industry.
|IMMU NM||Peers 54.07||IMMU NM||Peers 35.49|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
IMMU's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
IMMU's P/CF is negative making the measure meaningless.
|IMMU NM||Peers 59.83||IMMU NA||Peers 0.62|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
IMMU's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|IMMU 71.15||Peers 10.98||IMMU -37.83||Peers 32.42|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
IMMU is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, IMMU is expected to significantly trail its peers on the basis of its earnings growth rate.
|IMMU 85.66||Peers 330.50||IMMU -51.78||Peers 261.30|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
IMMU is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
IMMU significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV